The ETO protein of t(8;21) AML is a corepressor for the Bcl-6 B-cell 
Introduction
Hematologic malignancies often present with non-random translocations or mutations in genes encoding transcriptional regulatory proteins 1 . Such mutations alter the cell's genetic programming either by deregulating the expression of an important transcription regulator or, by altering its function, for example by changing a transcriptional activator into a repressor 2 . This can result in a block of differentiation, altered cell proliferation and self-renewal, or changes in the apoptotic set point of the cell. Unfortunately, the list of such mutations is very long and is still growing, raising the possibility that dozens of new disease subtypes may need to be classified and characterized. This complexity suggests that it will be difficult to identify specific molecular target based therapy that would be robust enough to benefit broad groups of patients.
On the other hand, among the complexity, common patterns can be discerned that suggests that common mechanisms are at play in hematologic malignancy that could offer specific remedies for a wide range of tumors. Many fusion proteins generated in leukemia involve transcriptional repressors that recruit histone deacetylases (HDACs) 3 . It is possible that cofactors (i.e.: corepressors) that link DNA binding factors,
HDACs and other components of the chromatin remodeling machinery may play a role in mediating disease as well. One possible mechanism is through aberrant fusion to transcriptional activators or by recruiting aberrant corepressors. An alternative scenario is that overexpression or deregulation of an oncogenic DNA-binding transcriptional repressor may yield disease and the co-factor hence plays a secondary yet crucial link in repression of target genes and initiation of the malignant process.
One such repressor is the fusion partner of AML-1 in t(8;21) AML, named ETO MTG8 (eight-twenty one).
ETO is a member of a highly conserved protein family that also includes MTGR1 and ETO-2 4-9 in mammals. ETO family proteins contain four conserved domains (reviewed in 10, 11 ) which include: i) the TAF 110 homology domain, ii) the hydrophobic heptad repeat (HHR domain), which mediates dimerization and interaction with corepressors 12, 13 , iii) the nervy domain (NHR3 domain), which interacts with the regulatory subunit of cAMP dependent kinase PKAII 14 , and, iv) a zinc finger domain (MYND domain) that mediates interaction with the nuclear co-repressors N-CoR and SMRT [15] [16] [17] [18] . In humans, ETO is normally expressed in hematopoietic CD34 cells, and peripheral blood lymphocytes 14, 19 . In t(8;21) AML, AMLonly.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From 1/ETO recruits corepressors and HDACs to AML-1 target genes, leading to aberrant transcriptional repression 15 . Furthermore, ETO represses transcription when tethered to DNA by a heterologous DNA binding motif 12, 20 . However, ETO itself is not a transcription factor since it does not specifically bind to DNA 21 .
Given that ETO is a nuclear protein that binds corepressors (such as SMRT and N-CoR) and HDACs but not DNA, we previously hypothesized that ETO itself might normally functional as a corepressor for DNAbinding transcriptional repressors. We have shown that ETO could interact with the PLZF (promyelocytic leukemia zinc finger) protein and its malignant counterpart, PLZF/RAR generated by the t(11;17) retinoid refractory variant of acute promyelocytic leukemia (APL) 22, 23 . This suggests that ETO might function as a corepressor protein involved in the pathogenesis of t(11;17) APL, since its binding to PLZF/RAR is through the PLZF motif and hence retinoid insensitive.
PLZF is a member of the BTB/POZ (bric a brac, tramtrack, broad complex/pox virus zinc finger) family of transcription factors, which also includes Bcl-6, the oncoprotein most frequently involved in human B-cell lymphomas (approximately 40% of patients) 24 . Overexpression or lack of downregulation of Bcl-6 in lymphoma can occur by translocation of the gene to a heterologous promoter or through somatic hypermutation of the Bcl-6 locus [24] [25] [26] . Bcl-6 is normally expressed in germinal center B cells 27 , and mediates cell survival and proliferation and possibly also blockade of terminal differentiation [28] [29] [30] [31] . In lymphomas, inappropriately timed expression of Bcl-6 is believed to block lymphocyte differentiation and immortalize the cells, leaving them competent to continue proliferating and vulnerable to mutagenesis by somatic hypermutation 30, 32 . Co-transfection experiments with artificial reporter constructs showed that Bcl-6 is a potent transcriptional repressor [33] [34] [35] . Repression by Bcl-6 is mainly dependent on its BTB/POZ domain, which mediates recruitment of SMRT/N-CoR/BCoR corepressors and HDACs [36] [37] [38] . In addition, Bcl-6 contains a second repression domain in a central region and an array of six C-terminal Krüppel-like C2H2 zinc fingers that specifically bind a consensus DNA sequence in target gene loci 28, 33, 34, 37, 39 .
Since ETO is expressed in peripheral blood lymphocytes and Bcl-6 is a critical repressor in B-cells we only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From hypothesized that ETO is a bona fide corepressor protein of Bcl-6. Thus, akin to SMRT and N-CoR, ETO would enhance transcriptional repression by multiple DNA binding transcription factors, including Bcl-6 and PLZF. Such an interaction would provide a mechanistic link between proteins targeted in different hematologic malignancies. Accordingly, we now show that ETO and Bcl-6 are in fact partner proteins that are co-expressed in normal and malignant B-cells. ETO enhanced the ability of Bcl-6 to repress transcription of both reporter genes and endogenous target genes and forms a complex with Bcl-6 on DNA together with Bcl-6 and its binding sites on the promoters of its endogenous target genes. These data indicate that ETO is a genuine transcriptional corepressor and that common elements link the transcriptional pathogenesis of acute leukemias and B-cell lymphomas. Immunohistochemistry: Paraffin tissue sections from the 6 lymphoma cases (5 DLCL and 1 FL) 3 tonsil controls were stained with polyclonal rabbit antiserum directed against the N-terminus of ETO.
Immunostaining was performed using an automated immunostainer (Ventana Medical Systems) according to a modified MIP protocol (Ventana Medical Systems) using the ChemMate ABC Peroxidase Secondary Detection System (Ventana Medical Systems). Prior to staining, the paraffin sections were incubated at 95 0 C for 40 minutes in Antigen Retrieval Citra Plus buffer (BioGenex).
Plasmids. All the ETO plasmids (HA, Gal DBD & GST) used were kindly provided by Scott Hiebert and were described previously 12, 17 . The Bcl-6 EF expression vector was previously described in 37 . The Bcl-6 constructs used in the GST pulldown experiments and the Bcl-6 ZF construct were PCR generated and cloned into the T7 plink vector or the EF vector respectively and sequenced 41 .
Coimmunoprecipitation and Immunoblotting. 293T cells were transfected with Fugene (Roche) with 2.5
µg of diverse HA-tag-ETO or Gal-DBD-ETO constructs and 2.5 µg of myc-tag-Bcl-6 plasmids. 24 h after transfection, cells were lysed (1% NP40, 60 mM TrisHcl pH=8, 150 mM NaCl with protease inhibitors 
GST Affinity Chromatography Assays
GST-ETO constructs were expressed as described in 
Results

Bcl-6 and ETO are co-expressed in normal and malignant B-cells
In humans, ETO is expressed in CD34 cells and peripheral blood lymphocytes 14, 19 . However, it was not known whether ETO was expressed in germinal center B cells, where Bcl-6 is normally expressed. To determine the expression of ETO in hematopoietic and lymphoid tissues we performed RT-PCR on a cDNA panel containing samples from human spleen, lymph node, thymus, tonsils and bone marrow. Since ETO family genes are highly similar, to minimize artifacts due to cross-hybridization, we designed two sets of specific primers complementary to ETO but not MTGR1 or ETO-2. These correspond to the coding sequence and the 3'untranslated region. We found that ETO and Bcl-6 mRNA were co-expressed in spleen, lymph node and tonsil ( Fig 1A) . Accordingly, Immunohistochemistry assays performed in normal human lymph node showed ETO expression in germinal center cells (where Bcl-6 is also expressed) as well as in the marginal zone lymphocytes (Fig 1B) .
Bcl-6 is most commonly de-regulated in DLBCL and follicular lymphomas (FL) 24, 43 . To determine whether ETO is expressed in these neoplasms we performed RT-PCR for both proteins in a panel of tumor tissue samples from patients with DLBCLs and one with FL ( 
Bcl-6 interacts in vivo with ETO
To determine whether Bcl-6 and ETO could interact in mammalian cells, we expressed Bcl-6 and ETO in 293T cells, immunoprecipitated with a polyclonal ETO antibody and immunoblotted for myc-tag Bcl-6 and HA-tag ETO ( Fig.2A ). Bcl-6 was observed only in immunoprecipitates from lysates containing both ETO and Bcl-6, but not in lysates lacking either ETO or Bcl-6. No co-immunoprecipitation of Bcl-6 was seen with pre-immune serum. In reciprocal experiments, myc-tag Bcl-6 was also able to specifically pull down HA-ETO (Fig. 2B) . Therefore ETO and Bcl-6 interact in vivo in mammalian cells. To establish the physiological For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 12 relevance of this interaction, lysates from Daudi and Raji B-cell lymphoma cells were immunoprecipitated using a polyclonal ETO antibody and immunoblotted for Bcl-6 with a monoclonal antibody (Fig.2B) . In both cell lines, Bcl-6 was enriched only in immunoprecipitates with ETO antibody but not with the pre-immune serum. Thus, endogenous ETO interacts with endogenous Bcl-6 in B-cell lymphoma cells.
ETO and Bcl-6 colocalize to nuclear speckles
In order to determine if ETO localized together with Bcl-6, we first established the level of expression of exogenous ETO or Bcl-6 required to reproduce the endogenous nuclear distribution (nuclear diffuse and speckled and nuclear speckled respectively) in 293 T cells and then performed co-localization studies.
Imaging of cell sections by confocal laser microscopy showed near total (~ 80-90 %) overlap of ETO with Bcl-6 nuclear speckles (Fig.3A) . The staining pattern was not seen in untransfected cells or when pre- For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From immune serum and an irrelevant monoclonal antibody were used (data not shown). Bleed-through across channels was prevented by imaging each channel independently at non-overlapping wavelengths. The staining pattern of endogenous ETO and Bcl-6 was then determined in Daudi and Raji cells. However, since Raji cell nuclei are lobulated and folded and harder to accurately score we focus here on Daudi cells.
As observed by others in peripheral blood lymphocytes 14 , we found abundant ETO in the cytoplasm of these lymphoid cells, although there was nuclear staining as well (Fig.3B) 
Mapping the interaction between ETO and Bcl-6.
Transcription factors and co-factors may interact in specific ways through defined motifs or regions. For example, the N-CoR, BCoR and SMRT corepressors bind to the BTB/POZ domain of Bcl-6 38 . Since both ETO and Bcl-6 interact with these co-repressors there is the potential for bridging effects to occur. To only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From determine the nature of the interaction between ETO and Bcl-6 we performed protein affinity chromatography using GST-ETO fusion proteins. Glutathione-agarose beads were coated with fusion proteins containing the conserved motifs of ETO and expression verified by SDS/PAGE-Coomassie blue staining of the purified products (Data not shown). Only a fragment containing amino acids 217-385 of ETO specifically bound to Bcl-6 (Fig.4A) . This region contains the HHR motif of ETO motif (that mediates ETO homo/heterodimerization) and a more proximal region that mediates the interaction with PLZF. It was not possible to perform this experiment with a shorter fragment lacking the HHR as the resulting fusion protein was highly insoluble.
To test whether this interaction occurs in vivo, we expressed a series of GAL4-DNA binding domain/ETO fusion proteins along with Bcl-6 in 293 T cells and performed co-immunoprecipitation experiments.
Consistent with our prior results, GAL4-ETO , GAL4-ETO 259-343 , and GAL4-ETO 300-385 interacted with
Bcl-6 while the N-terminal portion of ETO did not (Fig.4B) indicating that either the interaction surface is long; that there are several contacts for Bcl-6 within ETO, or that one of the fragments is interacting with
Bcl-6 through a third, bridging factor. For example, low levels of endogenous ETO (or possibly other ETO family members) in 293 T cells could interact with Bcl-6 and recruit the ETO 300-385 via the HHR domain. In contrast to in vitro studies, we found the C-terminal portion of ETO interacts with Bcl-6, although at much lower levels (right panels - Fig 4B) . This is likely due to bridging through proteins such as N-CoR or SMRT, both of which interact with the ETO C-terminal domain 15 and are present in 293T cells 31 . Therefore, we conclude that the central region of ETO, possibly including the HHR motif, contacts Bcl-6 and that the Cterminal domain might make secondary contacts with Bcl-6 through bridging by other factors.
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Bcl-6 interacts with ETO through the Krüppel-like Zinc finger domain.
Protein affinity chromatography experiments were performed with [ 35 S] methionine or cysteine-labeled in vitro-translated Bcl-6 deletion mutants, which were allowed to interact with GST-ETO fusion products (Fig.4A) . Of note, the BTB/POZ domain, which is the major repression domain of Bcl-6, does not interact with ETO. This indicates that ETO and the SMRT/N-CoR/BCoR corepressors interact with Bcl-6 through distinct mechanisms. Instead, the interaction was mapped to the Krüppel-like zinc finger domain of Bcl-6.
Further mapping of this region indicated that the fourth zinc finger was specifically required for binding the medial region of ETO that binds Bcl-6 (Fig 4A) .
To test whether the zinc finger domain of Bcl-6 is required for the interaction to occur in vivo, we transiently transfected the full length HA-epitope tagged ETO with the full length myc-Bcl-6 or with the GAL4-DNA binding domain-Bcl-6 deleted for the zinc finger region (Bcl-6 ZincF). Consistent with the in vitro data, little or no Bcl-6 ZincF interacted with ETO, confirming that the zinc finger array of Bc-6 is the major interaction site for ETO (Fig.4C ).
ETO interacts with DNA-bound Bcl-6.
To determine whether the Bcl-6 zinc fingers could interact simultaneously with ETO and DNA we performed electrophoretic mobility shift assays using artificial Bcl-6 binding site (B6BS), or cyclin D2 promoter Bcl-6 binding site probes (cyclin D2 is a natural target gene of Bcl- 6 28 ). When incubated with nuclear extracts of 293T cells co-transfected with ETO and Bcl-6 the probes yielded three prominent DNA-protein complexes (Fig.5 b, c and e) that were shifted in the presence of Bcl-6 antibodies. The complexes were competed by a 100-fold excess of unlabeled wild type probe but not a mutant Bcl-6 binding oligonucleotide. The Bcl-6 complexes were also supershifted or destabilized by the presence of an anti-ETO antibody in the reaction mixture, although but not by the IgG control. These results show that Bcl-6 can use its zinc fingers to simultaneously bind to ETO and DNA, indicating that ETO could be present at Bcl-6 target genes and influence the transcriptional activity of Bcl-6.
ETO enhances Bcl-6 transcriptional repression
Since ETO and Bcl-6 interact, we next asked whether ETO could modulate transcriptional repression by Bcl-6. 293 T cells were co-transfected with expression vectors for both proteins, along with a reporter construct containing four Bcl-6 binding sites upstream of a thymidine kinase promoter driving luciferase gene expression (B6BS-tk-luc). Bcl-6 specifically represses this reporter construct but not a reporter lacking Bcl-6 binding sites -(data not shown and 38 ), In our assays Bcl-6 repression was not altered by cotransfection of the empty vector used to express ETO (Fig.6A) . However, co-expression of ETO increased repression by Bcl-6 from 8 to 18-fold. ETO alone did not affect transcription of these reporter constructs. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Synthetic promoters in transfected episomal plasmids do not necessarily reflect the transcriptional regulatory mechanisms that take place in the genomic chromatin context. Therefore, we tested whether ETO could enhance Bcl-6 repression of one of its natural target genes, in this case the cyclin D2 gene 28 .
We measured levels of cyclinD2 transcript in mock-transfected 293 T cells vs. cells transfected with vectors expressing Bcl-6 or Bcl-6 plus ETO (Fig 6B) . A GFP expression vector was added to indicate cells that were successfully transfected. 24 hours after transfection, GFP positive cells were sorted by FACS and the RNA was extracted. Semi-quantitative RT-PCR for cyclin D2 mRNA showed that exogenous Bcl-6 repressed expression of the endogenous cyclin D2 gene by 50%, and co-transfection of ETO doubled Bcl-6 repression of the target gene (Fig 6B) . Repetition of these experiments using real-time PCR to quantify cyclin D2 expression more precisely confirmed that ETO doubled repression by Bcl-6 while ETO alone did not affect cyclinD2 mRNA (Fig 6C) .
To link the interaction between ETO, Bcl-6 and Bcl-6 target genes we determined whether ETO was present with Bcl-6 at the cyclin D2 promoter by performing chromatin immunoprecipitations (ChIPs). 293T cells were cotransfected with ETO and Bcl-6 and harvested after 24 hours. The cross-linked cell nuclei were sonicated to ~500 bp DNA fragments and immunoprecipitated with Bcl-6 and ETO antibodies.
Purified DNA was amplified using specific primers for the cyclin D2 promoter Bcl-6 binding site (Fig.6D ).
The 122bp product was seen only with ETO and Bcl-6 antibodies but not with the pre-immune serum.
These results suggest that ETO interacts with Bcl-6 while attached to its binding site on the cyclin D2 promoter in transfected cells.
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To determine the physiological relevance of the Bcl-6 ETO interaction we tested whether ETO is present on Bcl-6 target promoters in B-cell lymphoma cells. ChIP was performed using Bcl-6 and ETO antibodies on chromatin derived from Daudi cells and PCR was performed on the Bcl-6 binding site of the cyclin D2, MIP1 and CD69 promoters (previously identified direct Bcl-6 targets 28 ). Both ETO and Bcl-6 antibodies only.
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As a negative control, a Bcl-6 coding sequence region was not enriched by any of the antibodies. The presence of Bcl-6 and ETO at natural Bcl-6 target genes in vivo indicates that ETO is a bona fide cofactor that interacts with Bcl-6 and Bcl-6 target genes.
ETO enhances Bcl-6 transcription repression in an HDAC dependent manner.
Given the ability of ETO to interact with HDACs 12, 17 and that transcriptional repression by a GAL4-ETO fusion protein was impaired by histone deacetylase inhibitor drugs 20 , we tested whether ETO enhancement of Bcl-6 repression was dependent on histone deacetylase activity. The B6BS-tk-luc reporter was cotransfected with empty expression vector, with Bcl-6, or with Bcl-6 plus ETO in the presence of Suberoylanilide hydroxamic acid (SAHA), which is an HDAC inhibitor that is active in the micromolar range, vs. vehicle alone 44 . At a dose level of 2.5µM, SAHA abrogated repression by both Bcl-6 and the Bcl-6-ETO combination (Fig. 8 A) . Immunoblot analysis verified that these effects were not due to reductions of or ETO expression in the presence of SAHA (Fig. 8 B) . These results suggest that the enhanced transcriptional repression by ETO and Bcl-6 is mediated through the recruitment of HDAC activity to target promoters. 
Discussion
Our work stems from the hypothesis that the wild-type counterparts of leukemia oncoproteins might form common regulatory complexes that govern normal hematopoiesis 22 . In malignancy, these proteins would still associate but mutations in one of the members would disrupt normal gene regulation. Accordingly, our previous studies indicated that the ETO protein of t(8;21) AML interacts with and enhances repression by the PLZF protein and PLZF/RAR , its malignant counterpart in t(11;17) acute promyelocytic leukemia 22, 23 .
Recently, ETO was also found to interact with the Gfi-1 transcriptional repressor as well 45 . These results suggest that ETO might normally function as a corepressor for transcriptional repressors in both normal and malignant cells. However, additional data is required to establish that ETO is a bona fide corepressor. For Our current studies were designed to address these questions by determining whether ETO is a corepressor for the Bcl-6 B-cell lymphoma oncogenic transcriptional repressor. Accordingly, we found that ETO is endogenously expressed in lymphoid tissues and most importantly in B-cell lymphomas along with Bcl-6. We used specific RT-PCR primers for ETO that do not hybridize to ETO-2 or MTGR1 to establish that the PCR product obtained is specific. This is important since ETO is not expressed in the mouse hematopoietic system 46 . Together, our data and those of others, indicate that the expression profiles of ETO in mice and humans are different. Our data do not exclude that other ETO family members might also directly or indirectly interact with Bcl-6. Future studies of the functions and expression patterns of ETO-2 and MTGR1 are warranted to determine whether they too are corepressors, and whether they interact with overlapping or distinct partner proteins.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From From the structural standpoint, we were surprised to find that ETO binds to the fourth zinc finger of Bcl-6, the first assignment of a specific zinc finger of Bcl-6 to a protein-protein interaction. The fact that the zinc finger domain of Bcl-6 was required for recruitment of ETO, and that ETO, Bcl-6 and DNA form a complex, implies that the zinc fingers of Bcl-6 fold in such a way as to make contacts with DNA and partner proteins simultaneously. This is a novel finding since the only other example of a C2H2 Zinc finger domain forming a simultaneous complex with DNA and a heterologous protein is that of the YY1 Zinc fingers with SP1 and ATF/CREB 47, 48 . Maschle et al found that mutations introduced into either the third, fourth, fifth or sixth zinc finger abrogated DNA binding and transcriptional repression by Bcl-6. This was interpreted as indicating that each of these (including the fourth zinc finger) bind DNA 49 . However, another possibility is that zinc finger domains require a precise folding arrangement that is disrupted by mutations. The zinc fingers of Bcl-6 were also shown to associate with class II HDACs, although this association could not be narrowed down to a specific finger 49, 50 .
Although these data suggest that the zinc finger domain might function as an autonomous repression motif there are conflicting reports on this point. In a reporter assay with a Bcl-6 binding site containing reporter, Seyfert et. al. found that the zinc finger domain did not repress transcription 34 . The same group also reported that the zinc finger domain functioned as a weak dominant negative when expressed in Bcl-6
positive Raji cells, indicating that it either does not repress or that it represses less efficiently than full-length Bcl-6 51 . In contrast, a GAL4-zinc finger fusion construct inhibited transcriptional activation of a reporter gene containing LexA and GAL4 sites when it was activated by a LexA-VP16 fusion 49 and GAL4 fusions with Bcl-6 deletion mutants lacking the zinc fingers were partially impaired for transcriptional repression compared to full length Bcl-6 in reporter assays 52 . These experiments illustrate the difficulty of determining the functional contribution of the zinc finger domain to transcriptional repression, which is unlikely to be resolved by studying deletion mutants of Bcl-6. Bcl-6 binds directly to N-CoR/SMRT/BCoR corepressors through the BTB/POZ domain and ETO also binds to N-CoR and SMRT [16] [17] [18] . We propose that the binding of ETO to the Bcl-6 zinc finger domain could stabilize the interaction of Bcl-6 with SMRT and NCoR through its C-terminal domain. In this view, interaction of Bcl-6 with HDACs would be enhanced through the only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From formation of a stable complex in which all of these corepressors together provide the optimal platform for HDAC action at Bcl-6 target genes (Fig 9) . This scenario is also supported by the fact that ETO C-terminal constructs weakly interact with Bcl-6 in vivo but not in vitro, suggesting a bridging interaction with other corepressors.
Bcl-6 as well as PLZF interacts with the region of ETO containing amino acids 217 to 379, which includes the nuclear localization signal and helical heptad repeat domains.
Confocal microscopy studies with endogenous Bcl-6 or PLZF and ETO showed that subsets of ETO speckles colocalize with either Bcl-6 or PLZF speckles (this work and
31
). It is interesting that the same central region of ETO was shown to mediate localization of ETO to a specific population of nuclear speckles 53 . These speckles were in association with the nuclear matrix, which is the functional compartment for many transcription factors including PLZF and most likely Bcl-6 as well 23 . Accordingly, it is likely that by virtue of its binding to transcription factor partners such as Bcl-6 and PLZF, that the ETO central domain targets this corepressor to nuclear speckles that are sites of active transcriptional repression.
A major question to be addressed in future studies is the contribution of ETO to transcriptional and biological effects of Bcl-6 in B-cells. Loss of function studies will be difficult since i) ETO family members might partially or totally compensate for downregulation of ETO, ii) ETO may have unexpected functions in B cells related to nuclear cytoplasmatic transport and cytoplasmatic functions, and iii) ETO is likely to have In conclusion, our data indicate that ETO is a bona fide corepressor protein for Bcl-6 and functions at least in part through amplification of HDAC activity, consistent with the fact that ETO directly interacts with 12 . This is supported by the endogenous co-precipitation and colocalization of ETO and Bcl-6 and by the ETO enhancement of Bcl-6 repression of a specific reporter and an endogenous target gene. were sorted by FACS and the RNA was submitted to reverse transcription followed by real-time PCR for Cyclin D2 and GAPDH transcript. This experiment was done in triplicates to determine standard deviations.
The primers used here were first analyzed for their efficiency which was almost 100%. (D) 293T cells were cotransfected with ETO and Bcl-6. Chromatin immunoprecipitations were performed after 24h of with either rabbit N-terminal ETO antibody, rabbit polyclonal Bcl-6 antibody or a rabbit IgG control. The ChIP products were PCR amplified using primers surrounding the Bcl-6 binding site on the Cyclin D2 promoter. Normal rabbit serum (NRS) and H 2 0 controls are also shown.
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